NCT06357182View on ClinicalTrials.gov

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

March 8, 2026

Study Completion Date

May 29, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given SC

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Iadademstat

Given PO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

OTHER

Questionnaire Administration

Ancillary study

DRUG

Venetoclax

Given PO

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Oryzon Genomics S.A.
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Oryzon Genomics S.A.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT06357182 - Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter